Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Mallal

Showing results (11-20 of 175) with videos related to

Pageof 18
Sort By:
The Journal of Antimicrobial Chemotherapy|February 24, 2007
HLA-B*5701 screening for susceptibility to abacavir hypersensitivityAndrew Lucas, David Nolan, Simon Mallal
Journal of HIV Therapy|July 3, 2003
Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?David Nolan, Silvana Gaudieri, Simon Mallal
Plos One|July 6, 2007
Leveraging hierarchical population structure in discrete association studiesJonathan Carlson, Carl Kadie, Simon Mallal, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2026
Co-evolved Partners of Immunity: A Trait-Based Map of Human Keystone OrganismsAmir Asiaee, Natalie Mallal, Elizabeth Phillips, et al.
Antiviral Therapy|February 6, 2004
Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular levelDavid Nolan, Emma Hammond, Ian James, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 26, 2014
Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergyRebecca Pavlos, Simon Mallal, David Ostrov, et al.
AIDS (London, England)|December 7, 2006
Interaction between allelic variation in IL12B and CCR5 affects the development of AIDS: IL12B/CCR5 interaction and HIV/AIDSElwyn Gabutero, Corey Moore, Simon Mallal, et al.
Pharmacogenomics|December 16, 2005
Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back againAnnalise Martin, David Nolan, Coral-Ann Almeida, et al.
Pharmacogenomics|September 1, 2004
Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicityAnnalise M Martin, David Nolan, Silvana Gaudieri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2006
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort studyA Rauch, D Nolan, A Martin, et al.
Pageof 18

Showing results (11-20 of 175) with videos related to

Sort By:
Pageof 18
The Journal of Antimicrobial Chemotherapy|February 24, 2007
HLA-B*5701 screening for susceptibility to abacavir hypersensitivityAndrew Lucas, David Nolan, Simon Mallal
Journal of HIV Therapy|July 3, 2003
Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?David Nolan, Silvana Gaudieri, Simon Mallal
Plos One|July 6, 2007
Leveraging hierarchical population structure in discrete association studiesJonathan Carlson, Carl Kadie, Simon Mallal, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2026
Co-evolved Partners of Immunity: A Trait-Based Map of Human Keystone OrganismsAmir Asiaee, Natalie Mallal, Elizabeth Phillips, et al.
Antiviral Therapy|February 6, 2004
Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular levelDavid Nolan, Emma Hammond, Ian James, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 26, 2014
Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergyRebecca Pavlos, Simon Mallal, David Ostrov, et al.
AIDS (London, England)|December 7, 2006
Interaction between allelic variation in IL12B and CCR5 affects the development of AIDS: IL12B/CCR5 interaction and HIV/AIDSElwyn Gabutero, Corey Moore, Simon Mallal, et al.
Pharmacogenomics|December 16, 2005
Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back againAnnalise Martin, David Nolan, Coral-Ann Almeida, et al.
Pharmacogenomics|September 1, 2004
Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicityAnnalise M Martin, David Nolan, Silvana Gaudieri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2006
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort studyA Rauch, D Nolan, A Martin, et al.
Pageof 18